Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ProMIS Neurosciences Inc.PMN · Entity 6643 | Director | May 20, 2026 | May 22, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ProMIS Neurosciences Inc.
Report date May 20, 2026 · Filed May 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 5,500 |
Reported balance
After 2026-05-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-20 · Grant · Acquired 5,500 · Balance 5,500 F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. |
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.77 · Expires 2036-05-20 | Direct | 11,000 |
Reported balance
After 2026-05-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-20 · Grant · Acquired 11,000 · Balance 11,000 F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board.
F2: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 20, 2026 Filed May 22, 2026 20:34 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 11,000 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065771 · tm2615475-6_4seq1.xml · derivative · entry 2 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,000 Underlying: Common Shares · 11,000 shares Expires 2036-05-20 F2 · derivative.exercise_date: 25% of the shares subject to this option vested upon grant with the remaining shares vesting ratably over thirty-six months, subject to continued service on the Board. Read SEC document |
| May 20, 2026 Filed May 22, 2026 20:34 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 5,500 | $0.00 Strike: $10.77 | $0.00 |
DisclosureSEC source: 0001104659-26-065771 · tm2615475-6_4seq1.xml · derivative · entry 1 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Shares · 5,500 shares Expires 2036-05-20 F1 · derivative.exercise_date: The shares subject to this option shall vest in full on May 20, 2027, subject to continued service on the Board. Read SEC document |
| June 12, 2025 Filed Jun 16, 2025 21:04 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 20,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001374339-25-000004 · primary_doc.xml · derivative · entry 1 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Shares · 20,000 shares Expires 2035-06-12 F1 · derivative.exercise_date: The options shall vest in full on the earlier of the first anniversary of the Grant Date and June 12, 2026, subject to continued service on the Board. Read SEC document |
| October 03, 2024 Filed Oct 7, 2024 22:39 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | GrantOption (right to buy) · Derivative | 40,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001104659-24-106768 · tm2425760-3_4seq1.xml · derivative · entry 1 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires 2034-10-03 F1 · derivative.exercise_date: 33% of the shares subject to this option vested on October 3, 2024, and the balance shall vest ratably over the following 24 months, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| September 24, 2024 Filed Sep 24, 2024 22:56 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 70,000 | $1.30 | $91,028.00 |
DisclosureSEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 3 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 208,333 Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 22:56 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 70,000 | $1.28 | $89,656.00 |
DisclosureSEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 2 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,333 Read SEC document |
| September 20, 2024 Filed Sep 24, 2024 22:56 UTC | ProMIS Neurosciences Inc. PMN · Entity 6643 | PurchaseCommon Shares | 60,000 | $1.25 | $75,066.00 |
DisclosureSEC source: 0001374339-24-000003 · primary_doc.xml · nonDerivative · entry 1 Shafmaster Madge K. · CIK 0001927066 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,333 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.